CST, 38815T, PMEL/Melanoma gp100 (HMB45) Mouse Monoclonal Antibody

Monoclonal Antibody for studying PMEL. Validated for IHC Leica Bond,Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, PMEL/Melanoma gp100 (HMB45) Mouse Monoclonal Antibody (CST #38815) is ready to ship. Product Usage Information IHC Leica Bond: 1:800 - 1:3200 Immunohistochemistry (Paraffin): 1:400 - 1:1600 Storage Supplied in 10 mM PBS containing 0.05% BSA and 0.05% sodium azide. Stable for 36 months when stored at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles . A slight precipitate may be present, but will not interfere with antibody performance. Protocol Available protocols: IHC Leica Bond, Immunohistochemistry (Paraffin) Specificity / Sensitivity PMEL/Melanoma gp100 (HMB45) Mouse Monoclonal Antibody recognizes endogenous levels of total PMEL/Melanoma gp100 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with extract of pigmented melanoma metastases from lymph nodes. Background PMEL/Melanoma gp100 is a type 1 transmembrane glycoprotein primarily expressed in pigment cells of the skin and eye, and overexpressed in more than 75% of human melanomas (1-3). It is involved in the transformation of melanosomes from stage I to stage II, forming the fibrillar matrix necessary for pigmentation of the cell (4). The synthesis and modification of PMEL/Melanoma gp100 is done in the endoplasmic reticulum (ER) and transferred to the Golgi complex where it is cleaved into two disulfide-linked subunits, Mα and Mβ. The cleavage of the large luminal Mα fragment is required for the formation of the fibrils that are the structure for melanin synthesis (5,6). The ability for PMEL/Melanoma gp100 to form functional amyloids makes it an interesting protein to study when looking at pathological amyloids in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease (5,7). Due to melanocyte-restricted expression of this protein, PMEL/Melanoma gp100 is considered a tumor-associated antigen that can be targeted by immunotherapeutic approaches to treat melanoma (8-10). Alternate Names 95 kDa melanocyte-specific secreted glycoprotein; D12S53E; gp100; M-alpha; M-beta; ME20; ME20-M; ME20-S; ME20M; ME20S; Melanocyte protein mel 17; Melanocyte protein PMEL; Melanocyte protein Pmel 17; Melanocytes lineage-specific antigen GP100; Melanoma-associated ME20 antigen; melanosomal matrix protein17; P1; P100; P26; PME17; PMEL; Pmel 17; PMEL17; Premelanosome protein; Secreted melanoma-associated ME20 antigen; SI; SIL; SILV; silver (mouse homolog)-like; silver homolog (mouse); Silver locus protein homolog; Silver, mouse, homolog of Specification REACTIVITY: H SENSITIVITY: Endogenous Source/Isotype: Mouse IgG1 kappa